Divisions of Plastic and Reconstructive Surgery (S.L.M. and K.B.) and Colorectal Surgery (E.J.D. and K.L.M.) and Department of Orthopedic Surgery (M.T.H., E.P.W., M.J.Y., F.H.S., and P.S.R.), Mayo Clinic, Rochester, Minnesota.
J Bone Joint Surg Am. 2020 Nov 18;102(22):1956-1965. doi: 10.2106/JBJS.20.00135.
Sacral tumor resections require a multidisciplinary approach to achieve a cure and a functional outcome. Currently, there is no accepted classification system that provides a means to communicate among the multidisciplinary teams in terms of approach, osseous resection, reconstruction, and acceptable functional outcome. The purpose of this study was to report the outcome of sacral tumor resection based on our classification system.
In this study, 196 patients (71 female and 125 male) undergoing an oncologic en bloc sacrectomy were reviewed. The mean age (and standard deviation) was 49 ± 16 years, and the mean body mass index was 27.2 ± 6.4 kg/m. The resections included 130 sarcomas (66%). The mean follow-up was 7 ± 5 years.
Resections included total sacrectomy (Type 1A: 20 patients [10%]) requiring reconstruction, subtotal sacrectomy (Type 1B: 5 patients [3%]) requiring reconstruction, subtotal sacrectomy (Type 1C: 104 patients [53%]) not requiring reconstruction, hemisacrectomy (Type 2: 29 patients [15%]), external hemipelvectomy and hemisacrectomy (Type 3: 32 patients [16%]), total sacrectomy and external hemipelvectomy (Type 4: 5 patients [3%]), and hemicorporectomy (Type 5: 1 patient [1%]). The disease-specific survival was 66% at 5 years and 52% at 10 years. Based on the classification, the 5-year disease-specific survival was 34% for Type 1A, 100% for Type 1B, 71% for Type 1C, 65% for Type 2, 57% for Type 3, 100% for Type 4, and 100% for Type 5 (p < 0.001). Tumor recurrence occurred in 67 patients, including isolated local recurrence (14 patients), isolated metastatic disease (31 patients), and combined local and metastatic disease (22 patients). At 5 years, the local recurrence-free survival was 77% and the metastasis-free survival was 68%. Complications occurred in 153 patients (78%), most commonly wound complications (95 patients [48%]). Following the procedure, 154 patients (79%) were ambulatory, and the mean Musculoskeletal Tumor Society (MSTS93) score was 60% ± 23%.
Although resections of sacral malignancies are associated with complications, they can be curative in a majority of patients, with a majority of patients ambulatory with an acceptable functional outcome considering the extent of the resection. At our institution, this classification allows for communication between surgical teams and implies a surgical approach, staging, reconstruction, and potential functional outcomes.
Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.
骶骨肿瘤切除术需要多学科方法来实现治愈和功能结果。目前,尚无公认的分类系统能够在方法、骨切除、重建和可接受的功能结果方面为多学科团队提供沟通手段。本研究的目的是报告基于我们分类系统的骶骨肿瘤切除结果。
本研究回顾了 196 名接受肿瘤整块骶骨切除术的患者(71 名女性和 125 名男性)。平均年龄(标准差)为 49 ± 16 岁,平均体重指数为 27.2 ± 6.4kg/m。切除包括 130 例肉瘤(66%)。平均随访时间为 7 ± 5 年。
切除包括全骶骨切除术(1A 型:20 例[10%])需要重建,次全骶骨切除术(1B 型:5 例[3%])需要重建,次全骶骨切除术(1C 型:104 例[53%])不需要重建,半骶骨切除术(2 型:29 例[15%]),外半骨盆切除术和半骶骨切除术(3 型:32 例[16%]),全骶骨切除术和外半骨盆切除术(4 型:5 例[3%]),半骨盆切除术(5 型:1 例[1%])。5 年疾病特异性生存率为 66%,10 年为 52%。根据分类,1A 型 5 年疾病特异性生存率为 34%,1B 型为 100%,1C 型为 71%,2 型为 65%,3 型为 57%,4 型为 100%,5 型为 100%(p < 0.001)。67 例患者发生肿瘤复发,包括孤立局部复发(14 例)、孤立远处转移(31 例)和局部和远处转移并存(22 例)。5 年局部无复发生存率为 77%,远处无复发生存率为 68%。153 例患者(78%)发生并发症,最常见的是伤口并发症(95 例[48%])。手术后,154 例(79%)患者可活动,平均肌肉骨骼肿瘤学会(MSTS93)评分为 60%±23%。
尽管骶骨恶性肿瘤切除术与并发症相关,但在大多数患者中可以治愈,大多数患者可活动且功能结果可接受,考虑到切除的范围。在我们的机构中,这种分类允许手术团队之间进行沟通,并暗示了手术方法、分期、重建和潜在的功能结果。
治疗性 IV 级。有关证据水平的完整描述,请参见作者说明。